MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer

Summary

This is a phase Ib trial that evaluates the safety and tolerability of MK-2206 given in combination with exemestane +/- goserelin in pre- and post-menopausal patients with hormone receptor-positive metastatic breast cancer.

Timeline

Start

—

Primary completion

—

Completion

—

Outcome

Outcome not reported

Stopped (Enrollment): “Funding not available, study did not open to accrual and will not open in future”

Drugs

Indications